Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone Antibacterial

Clinical Pharmacokinetics

Volumn 42, Issue 13, 2003, Pages 1129-1140

  Stalker, Dennis J ^a,b   Jungbluth, Gail L ^a  

^a PFIZER INC   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; DEXTROMETHORPHAN; GENTAMICIN; LINEZOLID; OXAZOLIDINONE DERIVATIVE; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; SEROTONIN AGONIST; WARFARIN;

AGE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; ENTEROCOCCUS; FOOD DRUG INTERACTION; GENDER; GRAM POSITIVE BACTERIUM; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FUNCTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS; STREPTOCOCCUS;

ACETAMIDES; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; DRUG INTERACTIONS; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; OXAZOLIDINONES;

EID: 0242320209     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342130-00004     Document Type: Review

References (46)

1. Borek AP, Peterson LR, Noskin GA. Activity of linezolid against medically important gram-positive bacteria from 1997-2000 [abstract]. Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, Ontario, Canada
2. Jones RN, Ballow CH, Biedenbach DJ. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagn Microbiol Infect Dis 2001; 40 (1-2): 59-66
3. Noskin GA, Siddiqui F, Stosor V, et al. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 1999; 43: 2059-62
4. von Eiff C, Peters G. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. J Antimicrob Chemother 1999; 43: 569-73
5. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839-45
6. Swaney SM, Aoki H, Ganoza MC, et al. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42: 3251-5
7. Kloss P, Xiong L, Shinabarger DL, et al. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999; 294 (1): 93-101
8. Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001; 45 (7): 2154-6
9. Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 1998; 18: 456-62
10. Cammarata SK, Schueman LK, Timm JA, et al. Oral linezolid in the treatment of community-acquired pneumonia: a phase III trial [abstract 654]. Program and abstracts of the American Thoracic Society; 2000 May 5-10; Toronto, Ontario.
11. San Pedro GS, Cammarata SK, Oliphant TH, et al. Linezolid versus ceftrixone/cefpodoxime in patients hospitalised for the treatment of strepococcus pneumoniae pneumonia. Scand J Infect Dis 2002; 34: 720-8
12. Duvall SE, Seas C, Bruss JB, et al. Comparison of linezolid to oral clarithromycin in the treatment of uncomplicated skin infections: results from a multinational phase III trial [abstract]. Program and abstracts of the 9th International Congress on Infectious Disease; 2000 Apr 10-13; Buenos Aires, Argentina.
13. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of mehticillin-resistant staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1401-9
14. Rubinstein E, Cammarata SL, Oliphant TH, et al. Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32: 402-12
15. Stevens DL, Smith LG, Bruss JB, et al. Linezolid Skin and Soft Tissue Infections Study Group. Randomized comparison of linezolid (PNU-100766) versus oxacillin/dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44: 3408-13
16. Pawsey SD, Daley-Yates PT, Wajszczuk CP, et al. U-100766 safety, toleration and pharmacokinetics after oral and intravenous administration. Abstracts of European Congress of Antimicrobial Chemotherapy; 1996 May 15-17; Glasgow.
17. Stalker DJ, Jungbluth GL, Hopkins NK, et al. Pharmacokinetics and tolerance of single and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemo 2003; 51 (5): 1239-46
18. Welshman IR, Sisson TA, Jungbluth GL, et al. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos 2001; 22: 91-7
19. Welshman IR, Stalker DJ, Hopkins NK, et al. Linezolid: comparative bioavailability of single doses of 600mg tablet and oral suspension formulations. Data on file, Kalamazoo, USA: Pharmacia Corporation, 1998
20. Jungbluth GL, Welshman IR, Hopkins NK, et al. Linezolid: single-and multiple-dose pharmacokinetics evaluation of dose proportionality. Data on file, Kalamazoo, USA: Pharmacia Corporation, 1999
21. Cirincione B, Phillips L, Grasela T, et al. Influence of dose responses for linezolid efficacy using Monte Carlo simulations. Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists; 2000 Oct 29-Nov 2; Indianapolis (IN)
22. Rayner CR, Forrest A, Meagher AK, et al. Clinical pharmacokinetics of linezolid efficacy in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; In Press
23. 14C]linezolid to healthy human subjects. Drug Metab Dispos 2001; 29 (8): 1136-45
24. Lasher S, Jungbluth G, Hopkins N. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. J Clin Pharmacol 1999; 39 (12): 1277-82
25. Jungbuth GL, Lasher TA, Hopkins NK, et al. Linezolid and aztreonam: a pharmacokinetic evaluation of intravenous coadministration in healthy volunteers [abstract]. Clin Infect Dis 1997; 25 (2): 487
26. Chiba K, Uda F, Yamazaki S, et al. U-100766: In vitro protein binding of U-100766 in plasma of rats, dogs and humans. Data on file, Kalamazoo, USA: Pharmacia Corporation, 1995
27. Conte JE, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002 May; 46 (5): 1475-80
28. Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001; 45: 1843-6
29. Rana B, Murnaghan C, Butcher I, et al. Penetration of linezolid into osteo-articular tissues. Southampton, UK: The British Orthopaedic Research Society, 2001 Sep 24-25
30. Hopkins N, Welshman I, Jungbluth, et al. Linezolid bone levels after a single 600mg oral dose. Data on file, Kalamazoo, USA: Pharmacia Corporation, 2002
31. Wynalda MA, Hauer MJ, Wienkers LC. Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metab Dispos 2000; 28: 1014-7
32. Wienkers LC, Wynalda MA, Feenstra KL, et al. In vitro metabolism of linezolid (PNU-100766): lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999 Sep 26-29; San Francisco (CA)
33. Azie N, Stalker D, Jungbluth G, et al. Effect of linezolid on CYP2C9 using racemic warfarin (W) as a probe [abstract]. Clin Pharmacol Ther 2001; 69 (2): 21
34. Lasher Sisson T, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol 2002; 57: 793-7
35. Hendershot P, Jungbluth G, Cammarata S, et al. Pharmacokinetics of linezolid in patients with liver disease [abstract]. J Antimicrob Chemother 1999; 44 Suppl. A: 55
36. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47 (9): 2775-80
37. Zyvox® (linezolid): prescribing information. Peapack, NJ: Pharmacia Corporation, 2002 Jan. Available from URL: www.pharmacia.com/prescription/ PDF_Current/Zyvox.pdf [Accessed 2003 Sep 2]
38. Kearns GL, Abdel-Rahman SM, Blumer JL, et al. Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J 2000; 19 (12): 1178-84
39. Jungbluth GL. Linezolid injection: single dose pharmacokinetic assessment in pediatric patients following an intravenous infusion. Data on file, Kalamazoo, USA: Pharmacia Corporation, 2002
40. Jungbluth GL, Welshman IR, Hopkins NK, et al. Linezolid pharmacokinetics in adolescents. Proceedings of the Pediatric Academic Societies Annual Meeting. 2002 May 4-7; Baltimore (MD)
41. Jungbluth GL, Welshman IR, Hopkins NK, et al. Impact of gestational and postnatal age on linezolid disposition in neonates and young infants. Proceedings of the Pediatric Academic Societies Annual Meeting. 2002 May 4-7; Baltimore (MD)
42. Sweeney MT, Baldwin KF, Zurenko GE. In vitro activity of linezolid combined with other antibacterial agents. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco (CA)
43. Martin Jr JP, Herberg JT, Slatter JG, et al. Although a novel IV 364/18 microtitre plate assay demonstrates that linezolid (PNU-100766) is a weak competitive (reversible) inhibitor of human MAO-A, no clinical evidence of MAO-A inhibition in clinical trials has been observed. Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego (CA)
44. Martin JP, Dupuis MJ, Herberg JT. The development of microtiter plate-based assays for monoamine oxidases (MAO) A and B. Data on file, Kalamazoo, USA: Pharmacia Corporation, 1998
45. Antal EJ, Hendershot PE, Batts DH, et al. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using presser response to oral tyramine. J Clin Pharmacol 2001; 41 (5): 552-62
46. Hendershot PE, Antal EJ, Welshman IR, et al. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorphan HBr. J Clin Pharmacol 2001; 41 (5): 563-72